The Filing Desk

Alnylam Pharmaceuticals vs Royalty Pharma

Alnylam Pharmaceuticals ALNY · Royalty Pharma RPRX · Pharmaceuticals

Alnylam Pharmaceuticals reported revenue of $3.7 billion in fiscal 2025, 1.6 times Royalty Pharma's $2.4 billion in fiscal 2025. Alnylam Pharmaceuticals' revenue grew 65.2% in its latest year, and Royalty Pharma's grew 5.1%. Alnylam Pharmaceuticals had an operating margin of 13.5%, against 65.6% at Royalty Pharma.

Side by side

Alnylam PharmaceuticalsRoyalty Pharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$3.7B$2.4B
Revenue growth65.2%5.1%
Revenue growth a year, last 5 years49.8%2.3%
Gross margin81.8%—
Operating margin13.5%65.6%
Net margin8.4%32.4%
Free cash flow$465M—
Free cash flow margin12.5%—
Return on capital—8.9%
Net debt to EBITDA−3.4x5.3x
Dividends and buybacks$0M$1.2B
Change in diluted share count5.5%−5.0%
Last close$147.82$67.72
P/E at the last close63.4×44.3×
Insider trades, last 12 monthsbought $543,126, sold $23.3 millionsold $110.9 million
Piotroski F-score6 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Alnylam PharmaceuticalsRoyalty Pharma
Operating margin
Percent of revenue
Alnylam PharmaceuticalsRoyalty Pharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Alnylam PharmaceuticalsRoyalty Pharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alnylam Pharmaceuticals and Royalty Pharma pages.